NCT03589326 2025-11-26A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic LeukemiaTakedaPhase 3 Active not recruiting245 enrolled 15 charts 2 FDA
NCT03112603 2025-08-12A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)Incyte CorporationPhase 3 Completed330 enrolled 32 charts 2 FDA
NCT02393859 2024-05-29Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)AmgenPhase 3 Completed111 enrolled 23 charts 2 FDA